NOVARTIS AG-REG (1NOVN.MI) Stock Price & Overview

BIT:1NOVN • CH0012005267

Current stock price

131.94 EUR
+3.94 (+3.08%)
Last:

The current stock price of 1NOVN.MI is 131.94 EUR. Today 1NOVN.MI is up by 3.08%. In the past month the price increased by 10.87%.

1NOVN.MI Key Statistics

1-Month Range116 - 148
Current 1NOVN.MI stock price positioned within its 1-month range.
Market Cap
278.713B
P/E
17.16
Fwd P/E
17.05
EPS (TTM)
7.69
Dividend Yield
3.11%

1NOVN.MI Stock Performance

Today
+3.08%
1 Week
-1.54%
1 Month
+10.87%
3 Months
+16.76%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1NOVN.MI Stock Chart

NOVARTIS AG-REG / 1NOVN Daily stock chart

1NOVN.MI Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to 1NOVN.MI.


Chartmill TA Rating
Chartmill Setup Rating

1NOVN.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to 1NOVN.MI. Both the health and profitability get an excellent rating, making 1NOVN.MI a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1NOVN.MI Earnings

On February 4, 2026 1NOVN.MI reported an EPS of 2.03 and a revenue of 13.34B. The company missed EPS expectations (-0.17% surprise) and missed revenue expectations (-4.89% surprise).

Next Earnings DateApr 28, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$2.03
Revenue Reported13.336B
EPS Surprise -0.17%
Revenue Surprise -4.89%

1NOVN.MI Forecast & Estimates

34 analysts have analysed 1NOVN.MI and the average price target is 132.6 EUR. This implies a price increase of 0.5% is expected in the next year compared to the current price of 131.94.

For the next year, analysts expect an EPS growth of 0.69% and a revenue growth 2.53% for 1NOVN.MI


Analysts
Analysts70.59
Price Target132.6 (0.5%)
EPS Next Y0.69%
Revenue Next Year2.53%

1NOVN.MI Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

1NOVN.MI Financial Highlights

Over the last trailing twelve months 1NOVN.MI reported a non-GAAP Earnings per Share(EPS) of 7.69. The EPS increased by 14.98% compared to the year before.


Income Statements
Revenue(TTM)56.33B
Net Income(TTM)13.98B
Industry RankSector Rank
PM (TTM) 24.83%
ROA 12.6%
ROE 30.31%
Debt/Equity 0.64
Chartmill High Growth Momentum
EPS Q2Q%2.53%
Sales Q2Q%1.39%
EPS 1Y (TTM)14.98%
Revenue 1Y (TTM)8.91%

1NOVN.MI Ownership

Ownership
Inst Owners41.7%
Shares2.11B
Float1.87B
Ins Owners0.03%
Short Float %N/A
Short RatioN/A

About 1NOVN.MI

Company Profile

1NOVN logo image Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Company Info

IPO: 2001-05-07

NOVARTIS AG-REG

Lichtstrasse 35

Basel BASEL-STADT CH

Employees: 75267

1NOVN Company Website

1NOVN Investor Relations

Phone: 41613241111

NOVARTIS AG-REG / 1NOVN.MI FAQ

What does NOVARTIS AG-REG do?

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.


What is the current price of 1NOVN stock?

The current stock price of 1NOVN.MI is 131.94 EUR. The price increased by 3.08% in the last trading session.


Does 1NOVN stock pay dividends?

NOVARTIS AG-REG (1NOVN.MI) has a dividend yield of 3.11%. The yearly dividend amount is currently 3.48.


What is the ChartMill technical and fundamental rating of 1NOVN stock?

1NOVN.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Which stock exchange lists 1NOVN stock?

1NOVN.MI stock is listed on the Euronext Milan exchange.


What is the GICS sector and industry of 1NOVN stock?

NOVARTIS AG-REG (1NOVN.MI) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the ownership details for 1NOVN stock?

You can find the ownership structure of NOVARTIS AG-REG (1NOVN.MI) on the Ownership tab.